Información de Eli Lilly and Co, dividendo de Eli Lilly and Co, actividades de los accionistas y más

Más Datos de Eli Lilly and Co Compañía

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).

Información de Eli Lilly and Co



Símbolo de cotizaciónLLY

Nombre de la empresaEli Lilly and Co

Fecha de salida a bolsaJul 09, 1970

Director ejecutivoRicks (David A)

Número de empleados47000

Tipo de seguridadOrdinary Share

Fin del año fiscalJul 09

DirecciónLilly Corporate Ctr

CiudadINDIANAPOLIS

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal46285

Teléfono13172762000

Sitio Webhttps://www.lilly.com/

Símbolo de cotizaciónLLY

Fecha de salida a bolsaJul 09, 1970

Director ejecutivoRicks (David A)

Ejecutivos de Eli Lilly and Co



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. J. Erik Fyrwald

Independent Director

74.59K

+10.00%

Ms. Anne E. White

Executive Vice President, President - Lilly Neuroscience

74.21K

+8641.00%

Mr. Patrik Jonsson

Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA

54.13K

+9067.00%

Mr. Edgardo Hernandez

Executive Vice President, President - Manufacturing Operations

39.73K

-17.00%

Mr. Ilya Yuffa

Executive Vice President, President of Lilly International

26.26K

-1250.00%

Ms. Anat Hakim

Executive Vice President, General Counsel, Secretary

25.66K

-17875.00%

Dr. Katherine Baicker, Ph.D.

Independent Director

23.37K

+215.00%

Mr. Diogo Rau

Executive Vice President, Chief Information and Digital Officer

19.72K

+8618.00%

Mr. Lucas E. Montarce

Chief Financial Officer, Executive Vice President

14.69K

+715.00%

Mr. Eric Dozier

Executive Vice President, Chief People Officer

9.84K

+1337.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. J. Erik Fyrwald

Independent Director

74.59K

+10.00%

Ms. Anne E. White

Executive Vice President, President - Lilly Neuroscience

74.21K

+8641.00%

Mr. Patrik Jonsson

Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA

54.13K

+9067.00%

Mr. Edgardo Hernandez

Executive Vice President, President - Manufacturing Operations

39.73K

-17.00%

Mr. Ilya Yuffa

Executive Vice President, President of Lilly International

26.26K

-1250.00%

Ms. Anat Hakim

Executive Vice President, General Counsel, Secretary

25.66K

-17875.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Diabetes-Mounjaro

6.52B

37.02%

Diabetes-Zepbound

3.59B

20.39%

Oncology-Verzenio

1.47B

8.35%

Diabetes-Other Diabetes

1.06B

6.04%

Diabetes-Trulicity

1.05B

5.98%

Otro

3.91B

22.23%

Por regiónUSD

Nombre

Ganancia

Proporción

U.S.

11.30B

64.20%

Europe

3.50B

19.87%

Other foreign countries

1.69B

9.59%

China

560.40M

3.18%

Japan

554.70M

3.15%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Diabetes-Mounjaro

6.52B

37.02%

Diabetes-Zepbound

3.59B

20.39%

Oncology-Verzenio

1.47B

8.35%

Diabetes-Other Diabetes

1.06B

6.04%

Diabetes-Trulicity

1.05B

5.98%

Otro

3.91B

22.23%

Estadísticas de accionistas

Actualizado: mié., 12 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

Lilly Endowment, Inc.

9.72%

The Vanguard Group, Inc.

8.63%

PNC Investments LLC

5.41%

BlackRock Institutional Trust Company, N.A.

4.43%

State Street Investment Management (US)

3.67%

Otro

68.13%

Accionistas

Proporción

Lilly Endowment, Inc.

9.72%

The Vanguard Group, Inc.

8.63%

PNC Investments LLC

5.41%

BlackRock Institutional Trust Company, N.A.

4.43%

State Street Investment Management (US)

3.67%

Otro

68.13%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

45.55%

Investment Advisor/Hedge Fund

18.81%

Foundation

9.72%

Research Firm

2.04%

Pension Fund

1.95%

Bank and Trust

1.76%

Insurance Company

1.47%

Sovereign Wealth Fund

1.29%

Hedge Fund

0.74%

Otro

16.68%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

5966

788.98M

83.44%

-4.91M

2025Q3

5762

789.85M

83.53%

-6.48M

2025Q2

5717

798.76M

84.28%

+2.87M

2025Q1

5710

800.38M

84.44%

+5.04M

2024Q4

5528

795.43M

83.87%

+627.51K

2024Q3

5177

793.57M

83.49%

-5.03M

2024Q2

5068

795.80M

83.72%

-2.01M

2024Q1

4916

795.04M

83.62%

-6.22M

2023Q4

4670

799.46M

84.21%

-2.37M

2023Q3

4354

800.21M

84.30%

-1.19M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Lilly Endowment, Inc.

92.19M

9.75%

-6.46K

-0.01%

Dec 29, 2025

The Vanguard Group, Inc.

80.59M

8.52%

+541.95K

+0.68%

Sep 30, 2025

PNC Investments LLC

51.15M

5.41%

+70.46K

+0.14%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

41.90M

4.43%

+599.55K

+1.45%

Sep 30, 2025

State Street Investment Management (US)

34.73M

3.67%

+219.59K

+0.64%

Sep 30, 2025

Capital Research Global Investors

25.09M

2.65%

+4.33M

+20.87%

Sep 30, 2025

Fidelity Management & Research Company LLC

22.69M

2.4%

-1.67M

-6.86%

Sep 30, 2025

Geode Capital Management, L.L.C.

19.82M

2.1%

+1.69M

+9.32%

Sep 30, 2025

Capital World Investors

14.97M

1.58%

-2.66M

-15.11%

Sep 30, 2025

Wellington Management Company, LLP

14.56M

1.54%

+574.23K

+4.10%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

VanEck Pharmaceutical ETF

47.56%

iShares U.S. Pharmaceuticals ETF

25.23%

Harbor Health Care ETF

18.24%

Roundhill GLP-1 & Weight Loss ETF

16.7%

Health Care Select Sector SPDR Fund

14.06%

Proshares Ultra Health Care

13.57%

iShares U.S. Healthcare ETF

13.54%

Amplify Weight Loss Drug & Treatment ETF

11.93%

Fidelity MSCI Health Care Index ETF

11.73%

Goldman Sachs Future Health Care Equity ETF

10.84%

VanEck Pharmaceutical ETF

Proporción47.56%

iShares U.S. Pharmaceuticals ETF

Proporción25.23%

Harbor Health Care ETF

Proporción18.24%

Roundhill GLP-1 & Weight Loss ETF

Proporción16.7%

Health Care Select Sector SPDR Fund

Proporción14.06%

Proshares Ultra Health Care

Proporción13.57%

iShares U.S. Healthcare ETF

Proporción13.54%

Amplify Weight Loss Drug & Treatment ETF

Proporción11.93%

Fidelity MSCI Health Care Index ETF

Proporción11.73%

Goldman Sachs Future Health Care Equity ETF

Proporción10.84%

Dividendos



Un total de 15.37B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 08, 2025

LLY.NB Interim Cash Dividend of gross USD 1.73 paid on Mar 10, 2026 going ex on Feb 13, 2026

Feb 13, 2026

Mar 10, 2026

Feb 13, 2026

Oct 27, 2025

LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025

Nov 14, 2025

Dec 10, 2025

Nov 14, 2025

Jun 23, 2025

LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025

Aug 15, 2025

Sep 10, 2025

Aug 15, 2025

May 05, 2025

LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025

May 16, 2025

Jun 10, 2025

May 16, 2025

Dec 09, 2024

LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 10, 2025

Feb 14, 2025

Oct 28, 2024

LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024

Nov 15, 2024

Dec 10, 2024

Nov 15, 2024

Jun 24, 2024

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024

Aug 15, 2024

Sep 10, 2024

Aug 15, 2024

May 06, 2024

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024

May 16, 2024

Jun 10, 2024

May 15, 2024

Dec 08, 2023

LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024

Feb 15, 2024

Mar 08, 2024

Feb 14, 2024

Nov 01, 2023

LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023

Nov 15, 2023

Dec 08, 2023

Nov 14, 2023

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos